Cambrex to Exhibit at the 2010 International Pharmaceutical Federation PSWC & AAPS Meeting and Expo
Rick Offerman, Ph.D., Associate Director, Marketing Services
East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, "Cambrex") will be exhibiting at the 2010 International Pharmaceutical Federation Pharmaceutical Sciences World Congress (PSWC) & American Association of Pharmaceutical Sciences (AAPS) Meeting and Exposition, November 15-17 in New Orleans, Louisiana. Attendees are invited to visit Cambrex’s booth to learn about the Company’s wide range of custom development and manufacturing services as well as several innovative technologies for the pharmaceutical industry.
Cambrex offers small molecule APIs and process development services for proprietary APIs as well as technologies that enhance the efficacy of finished drug products. Camouflage™ drug delivery technology will be the focus of AAPS. Camouflage™ is a polymer resin-based drug delivery platform that provides improved drug stability, the ability to control drug release and taste masking as its major benefits and is a novel approach to dealing with many critical aspects of drug delivery. Cambrex has assisted innovator and generic drug companies in the commercialization of a number of important orally-dosed drug products based on this technology and Camouflage™ has been deployed in a variety of dosage forms.
Cambrex will also be showcasing its global development and manufacturing capabilities including specialized offerings related to controlled substances, High Potency Active Pharmaceutical Ingredients (HPAPIs) and highly energetic chemistries. Cambrex manufactures over 120 generic and proprietary APIs and advanced intermediate products and sells to most major innovator and generic pharma companies.
Cambrex will be exhibiting at Booth 1242 at the Morial Convention Center, New Orleans.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.